YYYousef Yousef

Yousef Yousef

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yousef Yousef has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    When Markets Shape AI Mental Health Self-Management Tools: Consequences for Serious Mental Illness

    by Lucy Smith, Yousef Yousef, Piotr Wasilewski, Hajira Dambha-Miller

    AI-enabled self-management health tools are increasingly promoted within health care policy as part of digital self-management models for mental health care. However, development is concentrated on scalable, low-intensity interventions for common conditions, such as anxiety and depression, rather than on populations with the greatest clinical need, such as those with serious mental illness (SMI). This includes schizophrenia-spectrum and bipolar disorders, which remain comparatively underserved, despite experiencing a disproportionate burden of morbidity and service use. However, the clinical features of SMI—comprising fluctuating symptoms, multimorbidity, and elevated risk—may limit the suitability of low-intensity AI-driven self-management tools designed for mild-to-moderate conditions. In this Viewpoint, we argue that the scarcity of AI-enabled self-management tools for SMI reflects a structural feature of current innovation systems rather than one of technical infeasibility alone. Market incentives, regulatory pathways, and fragmented research pipelines favor low-risk, high-volume populations, thereby limiting development for clinically complex groups. Addressing this unevenness is essential and will require upstream intervention, including targeted public funding, improved data infrastructure, and administrative frameworks that support safe innovation in high-risk populations. Embedding equity for SMI as a primary design requirement will be necessary to ensure that AI-driven mental health tools do not reinforce current inequalities.


  • Open Access

    Equity Considerations in AI-Enabled Conversational Systems: A Cross-Sectional Comparative Study of Clinical Responses

    by Lysanne Veerle Michels, Yousef Yousef, Heidi Smith, Hajira Dambha-Miller

    Background: Artificial intelligence (AI)-enabled conversational tools are increasingly used for health information and clinical decision support. Concerns persist regarding systematic bias, limited transparency, and the potential to exacerbate health inequity in real-world use. Empirical evaluation of how these tools operationalise equity-relevant factors in clinical responses remains limited. We aimed to compare the inclusion of equity considerations across widely used AI tools in response to standardised health queries.Methods: In this cross-sectional comparative study, we developed clinical and health information queries reflecting patient and clinician perspectives across common scenarios. Responses were generated using multiple widely used AI tools (ChatGPT, Claude, Copilot, DeepSeek, Doubao, Gemini, and Grok). Queries were standardised and geolocation controlled to minimise localisation effects. Responses were assessed using a structured framework with inclusion of equity-relevant factors (age, sex or gender, ethnicity, socioeconomic context, and access to care), clarity of clinical guidance, and specification of non-diagnostic outputs.Findings: Substantial heterogeneity was observed. Grok demonstrated the highest inclusion of equity-relevant factors, followed by Claude and DeepSeek, whereas Doubao showed minimal inclusion. ChatGPT, Copilot, and Gemini showed intermediate performance. Age was referenced in over half of responses, whereas sex or gender and ethnicity were included in fewer than half. Socioeconomic context and access to care were infrequently represented. Although all AI tools provided clinical guidance, fewer than half explicitly specified outputs as non-diagnostic. Patterns of equity inclusion varied by geographic context across tools.Interpretation: AI tools demonstrate inconsistent and limited operationalisation of equity-relevant factors, with implications for clinical safety and differential performance across populations. Strengthening transparency requirements, embedding standardised equity evaluation frameworks, and aligning regulatory oversight with real-world deployment are essential to ensure these technologies mitigate rather than exacerbate health inequity.

  • Open Access

    When Markets Shape AI Mental Health Self-Management Tools: Implications for Serious Mental Illness (Preprint)

    by Lucy Smith, Yousef Yousef, Piotr Wasilewski, Hajira Dambha-Miller

    UNSTRUCTURED Artificial intelligence (AI)-enabled health tools are increasingly promoted within healthcare policy as part of digital self-management models for mental health care. However, development is concentrated on scalable, low-intensity interventions for common conditions such as anxiety and depression, rather than on populations with the greatest clinical need, such as those with serious mental illness (SMI). This includes schizophrenia-spectrum and bipolar disorders, for example, which remain comparatively underserved, although experiencing a disproportionate burden of morbidity and service use. The clinical features of SMI -comprising fluctuating symptoms, multimorbidity, and elevated risk limit the suitability of low-intensity AI-driven self-management tools designed for mild-to-moderate conditions. This Viewpoint argues that the scarcity of AI-enabled self-management tools for SMI reflects a common issue in current innovation systems rather than one of technical infeasibility alone. Market incentives, regulatory pathways, and fragmented research pipelines favour low-risk, high-volume populations, while limiting development for clinically complex groups. Addressing this unevenness is essential and will require upstream intervention, including targeted public funding, improved data infrastructure, and administrative frameworks that support safe innovation in high-risk populations. Embedding equity for SMI as a primary design requirement will be necessary to ensure that AI-driven mental health tools do not reinforce current inequalities.

  • Open Access

    Streamlining regulation to Unlock Digital Health Innovation in the NHS

    by Yousef Yousef, Jacob Keast, Hajira Dambha-Miller

    Digital health adoption in the National Health Service (NHS) remains fragmented despite significant technological advances and substantial government investment in innovation initiatives. Many promising digital solutions fail to progress beyond pilot phases, with implementation remaining inconsistent across trusts despite national strategies including the 2022 digital health and social care plan. This Viewpoint examines the principal obstacles to digital health commercialisation within the NHS, focusing on regulatory complexity, organisational fragmentation, limited financial capacity and cultural resistance to change. We review existing support mechanisms including the Digital Technology Assessment Criteria (DTAC), NHS Innovation Accelerator and Clinical Entrepreneur Programme, highlighting their strengths and persistent limitations. To accelerate adoption, we propose two key reforms: formalising DTAC as a mandatory national standard with subsidised compliance pathways for small and medium-sized enterprises, and establishing a national ‘innovation passport’ that harmonises DTAC, Medicines and Healthcare products Regulatory Agency and procurement requirements into a single, transferable assessment. These reforms, complemented by strengthened procurement coordination and cultural change initiatives, could create a more predictable pathway for digital innovation while maintaining rigorous patient safety standards and enabling equitable access to validated digital health tools across the NHS.


  • Open Access

    The Cost of Social Care Need in People with Multimorbidity: A Population-Based Cohort Study of 5.7 million Individuals

    by Tassella Isaac, Aman Jat, Lucy Smith, Yousef Yousef, Rishika Vashishtha, Mehedi Hasan, Hajira Dambha-Miller

    Background: Multimorbidity (the coexistence of two or more long-term conditions) is increasingly prevalent, particularly among older adults, and is a major driver of healthcare expenditure. However, healthcare costs reflect only part of the overall burden. Many people with multimorbidity also depend on social care services for personal support, mobility assistance, and social engagement to preserve independence and quality of life. Despite its significance for individuals, families, and the health system, the economic impact of social care needs related to multimorbidity has not been quantified at a population level in England. Methods: We conducted a retrospective, population-based cohort study of adults (≥18 years) with multimorbidity using data from the CPRD Gold and Aurum datasets covering 1987–2020. Social care needs were identified through coded indicators across three domains (personal care, mobility, and social interaction) and valued using 2019–2020 national unit costs from the Personal Social Services Research Unit (PSSRU). Adjusted per-capita costs were estimated via direct standardisation by age, sex, ethnicity, and socioeconomic deprivation. Results: The cohort comprised 5,771,603 adults with multimorbidity (mean age 56.5 years; 55.1% female). Among them, 800,309 individuals (13.9%) had at least one recorded social care need. Personal care accounted for the majority of costs (£3.66 billion; 84.3% of total), affecting 7.3% of the cohort with a mean annual expenditure of £8,736 per user. Mobility needs represented £336.8 million (7.8%) and social interaction needs £346 million (8.0%), with mean annual costs of £1,426 and £709 per user, respectively. Individuals with multiple needs (6.3% of the cohort) incurred mean annual costs of £9,076. Social care needs and costs were higher among older adults, women, and those living in more deprived areas. Conclusion: This study provides the first population-level estimate of social care costs associated with multimorbidity in England. Social care represents an important yet often overlooked component of the broader economic burden of multimorbidity. Costs are predominantly concentrated in personal care and vary systematically by demographic and socioeconomic factors, underscoring potential inequities in service access or provision. Integrating social care within multimorbidity strategies is essential to address the full scale of its societal impact.